American Psychiatric A, American Psychiatric A, Force DSMT. Diagnostic and statistical manual of mental disorders: DSM-5. 2013.
McCuen-Wurst C, Ruggieri M, Allison KC. Disordered eating and obesity: associations between binge-eating disorder, night-eating syndrome, and weight-related comorbidities. Ann N Y Acad Sci. 2018;1411:96–105.
Google Scholar
Ghaderi A, Odeberg J, Gustafsson S, Råstam M, Brolund A, Pettersson A. et al. Psychological, pharmacological, and combined treatments for binge eating disorder: a systematic review and meta-analysis. PeerJ. 2018;6:e5113
Google Scholar
Wilson GT, Wilfley DE, Agras WS, Bryson SW. Psychological treatments of binge eating disorder. Arch Gen Psychiatry. 2010;67:94–101.
Google Scholar
Linardon J. Rates of abstinence following psychological or behavioral treatments for binge-eating disorder: meta-analysis. Int J Eat Disord. 2018;51:785–97.
Google Scholar
Appolinario JC, Nardi AE, McElroy SL. Investigational drugs for the treatment of binge eating disorder (BED): an update. Expert Opin Invest Drugs. 2019;28:1081–1094.
Google Scholar
McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72:235–46.
Google Scholar
McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology. 2016;41:1251–60.
Google Scholar
Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74:903–10.
Google Scholar
Pursey KM, Stanwell P, Gearhardt AN, Collins CE, Burrows TL. The prevalence of food addiction as assessed by the Yale Food Addiction Scale: a systematic review. Nutrients. 2014;6:4552–90.
Google Scholar
Innamorati M, Imperatori C, Balsamo M, Tamburello S, Belvederi Murri M, Contardi A, et al. Food Cravings Questionnaire-Trait (FCQ-T) discriminates between obese and overweight patients with and without binge eating tendencies: the Italian version of the FCQ-T. J Pers Assess. 2014;96:632–9.
Google Scholar
Schulte EM, Grilo CM, Gearhardt AN. Shared and unique mechanisms underlying binge eating disorder and addictive disorders. Clin Psychol Rev. 2016;44:125–39.
Google Scholar
Fletcher PC, Kenny PJ. Food addiction: a valid concept? Neuropsychopharmacology. 2018;43:2506–13.
Google Scholar
Meule A, Küppers C, Harms L, Friederich HC, Schmidt U, Blechert J, et al. Food cue-induced craving in individuals with bulimia nervosa and binge-eating disorder. PloS ONE. 2018;13:e0204151.
Google Scholar
Wonderlich JA, Breithaupt LE, Crosby RD, Thompson JC, Engel SG, Fischer S. The relation between craving and binge eating: integrating neuroimaging and ecological momentary assessment. Appetite. 2017;117:294–302.
Google Scholar
Carlier N, Marshe VS, Cmorejova J, Davis C, Müller DJ. Genetic similarities between compulsive overeating and addiction phenotypes: a case for “food addiction”? Curr Psychiatry Rep. 2015;17:96.
Google Scholar
Brown RM, Kupchik YM, Spencer S, Garcia-Keller C, Spanswick DC, Lawrence AJ, et al. Addiction-like synaptic impairments in diet-induced obesity. Biol Psychiatry. 2017;81:797–806.
Google Scholar
Johnson PM, Kenny PJ. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. Nat Neurosci. 2010;13:635–41.
Google Scholar
Wiers CE, Zhao J, Manza P, Murani K, Ramirez V, Zehra A, et al. Conscious and unconscious brain responses to food and cocaine cues. Brain Imaging Behav. 2021;15:311–9.
Google Scholar
Volkow ND, Wise RA, Baler R. The dopamine motive system: implications for drug and food addiction. Nat Rev Neurosci. 2017;18:741–52.
Google Scholar
Volkow ND, Wang GJ, Fowler JS, Tomasi D, Baler R. Food and drug reward: overlapping circuits in human obesity and addiction. Curr Top Behav Neurosci. 2012;11:1–24.
Google Scholar
Grilo CM, White MA, Masheb RM. DSM-IV psychiatric disorder comorbidity and its correlates in binge eating disorder. Int J Eat Disord. 2009;42:228–34.
Google Scholar
Schreiber LR, Odlaug BL, Grant JE. The overlap between binge eating disorder and substance use disorders: diagnosis and neurobiology. J Behav Addict. 2013;2:191–8.
Google Scholar
Gearhardt AN, Corbin WR, Brownell KD. Preliminary validation of the Yale Food Addiction Scale. Appetite 2009;52:430–6.
Google Scholar
Gearhardt AN, White MA, Masheb RM, Morgan PT, Crosby RD, Grilo CM. An examination of the food addiction construct in obese patients with binge eating disorder. Int J Eat Disord. 2012;45:657–63.
Google Scholar
Hebebrand J, Gearhardt AN. The concept of “food addiction” helps inform the understanding of overeating and obesity: NO. Am J Clin Nutr. 2021;113:268–73.
Finlayson G. Food addiction and obesity: unnecessary medicalization of hedonic overeating. Nat Rev Endocrinol. 2017;13:493–8.
Google Scholar
Gearhardt AN, Hebebrand J. The concept of “food addiction” helps inform the understanding of overeating and obesity: YES. Am J Clin Nutr. 2021;113:263–67.
Chakravorty S, Vandrey RG, He S, Stein MD. Sleep management among patients with substance use disorders. Med Clin North Am. 2018;102:733–43.
Google Scholar
Roehrs TA, Roth T. Sleep disturbance in substance use disorders. Psychiatr Clin North Am. 2015;38:793–803.
Google Scholar
Logan RW, Hasler BP, Forbes EE, Franzen PL, Torregrossa MM, Huang YH, et al. Impact of sleep and circadian rhythms on addiction vulnerability in adolescents. Biol Psychiatry. 2018;83:987–96.
Google Scholar
Falcón E, McClung CA. A role for the circadian genes in drug addiction. Neuropharmacology. 2009;56:91–96.
Google Scholar
Lydon-Staley DM, Cleveland HH, Huhn AS, Cleveland MJ, Harris J, Stankoski D, et al. Daily sleep quality affects drug craving, partially through indirect associations with positive affect, in patients in treatment for nonmedical use of prescription drugs. Addictive Behav. 2017;65:275–82.
Google Scholar
Angarita GA, Canavan SV, Forselius E, Bessette A, Pittman B, Morgan PT. Abstinence-related changes in sleep during treatment for cocaine dependence. Drug Alcohol Depend. 2014;134:343–7.
Google Scholar
James MH, Aston-Jones G. Introduction to the Special Issue: “making orexin-based therapies for addiction a reality: what are the steps from here?”. Brain Res. 2020;1731:146665.
Google Scholar
American Academy of Sleep M. International Classification of Sleep Disorders—Third Edition (ICSD-3). Diagnostic and coding manual. 2014.
Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014;146:1387–94.
Google Scholar
Watson R, Bakos L, Compton P, Gawin F. Cocaine use and withdrawal: the effect on sleep and mood. Am J Drug Alcohol Abuse. 1992;18:21–28.
Google Scholar
Johanson CE, Roehrs T, Schuh K, Warbasse L. The effects of cocaine on mood and sleep in cocaine-dependent males. Exp Clin Psychopharmacol. 1999;7:338–46.
Google Scholar
Young-McCaughan S, Miaskowski C. Measurement of opioid-induced sedation. Pain Manag Nurs. 2001;2:132–49.
Google Scholar
Young-McCaughan S, Miaskowski C. Definition of and mechanism for opioid-induced sedation. Pain Manag Nurs. 2001;2:84–97.
Google Scholar
Lewis SA, Oswald I, Evans JI, Akindele MO, Tompsett SL. Heroin and human sleep. Electroencephalogr Clin Neurophysiol. 1970;28:374–81.
Google Scholar
Kenny TE, Van Wijk M, Singleton C, Carter JC. An examination of the relationship between binge eating disorder and insomnia symptoms. Eur Eat Disord Rev. 2018;26:186–96.
Google Scholar
Vardar E, Caliyurt O, Arikan E, Tuglu C. Sleep quality and psychopathological features in obese binge eaters. Stress Health. 2004;20:35–41.
Google Scholar
Trace SE, Thornton LM, Runfola CD, Lichtenstein P, Pedersen NL, Bulik CM. Sleep problems are associated with binge eating in women. Int J Eat Disord. 2012;45:695–703.
Google Scholar
Yeh SS, Brown RF. Disordered eating partly mediates the relationship between poor sleep quality and high body mass index. Eat Behav. 2014;15:291–7.
Google Scholar
Tzischinsky O, Latzer Y. Sleep-wake cycles in obese children with and without binge-eating episodes. J Paediatr Child Health. 2006;42:688–93.
Google Scholar
Kim KR, Jung YC, Shin MY, Namkoong K, Kim JK, Lee JH. Sleep disturbance in women with eating disorder: prevalence and clinical characteristics. Psychiatry Res. 2010;176:88–90.
Google Scholar
Ulman TF, Von Holle A, Torgersen L, Stoltenberg C, Reichborn-Kjennerud T, Bulik CM. Sleep disturbances and binge eating disorder symptoms during and after pregnancy. Sleep. 2012;35:1403–11.
Google Scholar
Kessler RC, Berglund PA, Chiu WT, Deitz AC, Hudson JI, Shahly V, et al. The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry. 2013;73:904–14.
Google Scholar
Ogilvie RP, Patel SR. The epidemiology of sleep and obesity. Sleep Health. 2017;3:383–8.
Google Scholar
Li JTE, Pursey KM, Duncan MJ, Burrows T. Addictive eating and its relation to physical activity and sleep behavior. Nutrients. 2018;10:10
Marino M, Li Y, Rueschman MN, Winkelman JW, Ellenbogen JM, Solet JM. et al. Measuring sleep: accuracy, sensitivity, and specificity of wrist actigraphy compared to polysomnography. Sleep. 2013;36:1747–55.
Google Scholar
Manni R, Ratti MT, Tartara A. Nocturnal eating: prevalence and features in 120 insomniac referrals. Sleep. 1997;20:734–8.
Google Scholar
Rogers NL, Dinges DF, Allison KC, Maislin G, Martino N, O’Reardon JP. et al. Assessment of sleep in women with night eating syndrome. Sleep. 2006;29:814–9.
Google Scholar
Cleator J, Abbott J, Judd P, Sutton C, Wilding JP. Night eating syndrome: implications for severe obesity. Nutr Diabetes. 2012;2:e44
Google Scholar
Allison KC, Lundgren JD, O’reardon JP, Geliebter A, Gluck ME, Vinai P, et al. Proposed diagnostic criteria for night eating syndrome. Int J Eat Disord. 2010;43:241–7.
Google Scholar
Kucukgoncu S, Midura M, Tek C. Optimal management of night eating syndrome: challenges and solutions. Neuropsychiatr Dis Treat. 2015;11:751–60.
Google Scholar
Stunkard AJ, Grace WJ, Wolff HG. The night-eating syndrome; a pattern of food intake among certain obese patients. Am J Med. 1955;19:78–86.
Google Scholar
Stunkard AJ. Eating patterns and obesity. Psychiatr Q. 1959;33:284–95.
Google Scholar
Lundgren JD, Allison KC, O’Reardon JP, Stunkard AJ. A descriptive study of non-obese persons with night eating syndrome and a weight-matched comparison group. Eat Behav. 2008;9:343–51.
Google Scholar
Sassaroli S, Ruggiero GM, Vinai P, Cardetti S, Carpegna G, Ferrato N, et al. Daily and nightly anxiety among patients affected by night eating syndrome and binge eating disorder. Eat Disord. 2009;17:140–5.
Google Scholar
Allison KC, Grilo CM, Masheb RM, Stunkard AJ. Binge eating disorder and night eating syndrome: a comparative study of disordered eating. J Consult Clin Psychol. 2005;73:1107–15.
Google Scholar
Corwin RL, Babbs RK. Rodent models of binge eating: are they models of addiction? ILAR J. 2012;53:23–34.
Google Scholar
Corwin RL, Avena NM, Boggiano MM. Feeding and reward: perspectives from three rat models of binge eating. Physiol Behav. 2011;104:87–97.
Google Scholar
Bello NT, Yeh CY, James MH. Reduced sensory-evoked locus coeruleus-norepinephrine neural activity in female rats with a history of dietary-induced binge eating. Front Psychol. 2019;10:1966.
Google Scholar
Moore CF, Leonard MZ, Micovic NM, Miczek KA, Sabino V, Cottone P. Reward sensitivity deficits in a rat model of compulsive eating behavior. Neuropsychopharmacology. 2020;45:589–96.
Google Scholar
Velázquez-Sánchez C, Ferragud A, Moore CF, Everitt BJ, Sabino V, Cottone P. High trait impulsivity predicts food addiction-like behavior in the rat. Neuropsychopharmacology. 2014;39:2463–72.
Google Scholar
Perello M, Valdivia S, García Romero G, Raingo J. Considerations about rodent models of binge eating episodes. Front Psychol. 2014;5:372.
Google Scholar
Berner LA, Bocarsly ME, Hoebel BG, Avena NM. Baclofen suppresses binge eating of pure fat but not a sugar-rich or sweet-fat diet. Behav. Pharmacol. 2009;20:631–4.
Google Scholar
Davis JF, Melhorn SJ, Shurdak JD, Heiman JU, Tschöp MH, Clegg DJ, et al. Comparison of hydrogenated vegetable shortening and nutritionally complete high-fat diet on limited access-binge behavior in rats. Physiol Behav. 2007;92:924–30.
Google Scholar
Howard CE, Porzelius LK. The role of dieting in binge eating disorder: etiology and treatment implications. Clin Psychol Rev. 1999;19:25–44.
Google Scholar
Bello NT, Guarda AS, Terrillion CE, Redgrave GW, Coughlin JW, Moran TH. Repeated binge access to a palatable food alters feeding behavior, hormone profile, and hindbrain c-Fos responses to a test meal in adult male rats. Am J Physiol Regul Integr Comp Physiol. 2009;297:R622–631.
Google Scholar
Anversa RG, Campbell EJ, Ch’ng SS, Gogos A, Lawrence AJ, Brown RM. A model of emotional stress-induced binge eating in female mice with no history of food restriction. Genes Brain Behav. 2020;19:e12613.
Google Scholar
Corwin RL. Binge-type eating induced by limited access in rats does not require energy restriction on the previous day. Appetite. 2004;42:139–42.
Google Scholar
Corwin RL, Buda-Levin A. Behavioral models of binge-type eating. Physiol Behav. 2004;82:123–30.
Google Scholar
Hagan MM, Wauford PK, Chandler PC, Jarrett LA, Rybak RJ, Blackburn K. A new animal model of binge eating: key synergistic role of past caloric restriction and stress. Physiol Behav. 2002;77:45–54.
Google Scholar
Cottone P, Wang X, Park JW, Valenza M, Blasio A, Kwak J, et al. Antagonism of sigma-1 receptors blocks compulsive-like eating. Neuropsychopharmacology. 2012;37:2593–604.
Google Scholar
Venner A, Todd WD, Fraigne J, Bowrey H, Eban-Rothschild A, Kaur S. et al. Newly identified sleep-wake and circadian circuits as potential therapeutic targets. Sleep. 2019;42:5
Google Scholar
Scammell TE, Arrigoni E, Lipton JO. Neural circuitry of wakefulness and sleep. Neuron. 2017;93:747–65.
Google Scholar
Eban-Rothschild A, Appelbaum L, de Lecea L. Neuronal mechanisms for sleep/wake regulation and modulatory drive. Neuropsychopharmacology. 2018;43:937–52.
Google Scholar
Bjorness TE, Greene RW. Interaction between cocaine use and sleep behavior: a comprehensive review of cocaine’s disrupting influence on sleep behavior and sleep disruptions influence on reward seeking. Pharmacol Biochem Behav. 2021;206:173194.
Google Scholar
Doyle SE, Feng H, Garber G, Menaker M, Lynch WJ. Effects of circadian disruption on methamphetamine consumption in methamphetamine-exposed rats. Psychopharmacology. 2015;232:2169–79.
Google Scholar
Mistlberger RE. Circadian food-anticipatory activity: formal models and physiological mechanisms. Neurosci Biobehav Rev. 1994;18:171–95.
Google Scholar
Gooley JJ, Schomer A, Saper CB. The dorsomedial hypothalamic nucleus is critical for the expression of food-entrainable circadian rhythms. Nat Neurosci. 2006;9:398–407.
Google Scholar
Mistlberger RE. Food-anticipatory circadian rhythms: concepts and methods. Eur J Neurosci. 2009;30:1718–29.
Google Scholar
Mistlberger R, Rusak B. Palatable daily meals entrain anticipatory activity rhythms in free-feeding rats: dependence on meal size and nutrient content. Physiol Behav. 1987;41:219–26.
Google Scholar
Mendoza J, Angeles-Castellanos M, Escobar C. Entrainment by a palatable meal induces food-anticipatory activity and c-Fos expression in reward-related areas of the brain. Neuroscience. 2005;133:293–303.
Google Scholar
Blancas A, González-Garcí a SD, Rodríguez K, Escobar C. Progressive anticipation in behavior and brain activation of rats exposed to scheduled daily palatable food. Neuroscience. 2014;281:44–53.
Google Scholar
Hsu CT, Patton DF, Mistlberger RE, Steele AD. Palatable meal anticipation in mice. PLoS ONE. 2010;5:9.
Flôres DE, Bettilyon CN, Yamazaki S. Period-independent novel circadian oscillators revealed by timed exercise and palatable meals. Sci Rep. 2016;6:21945.
Google Scholar
Velázquez-Sánchez C, Santos JW, Smith KL, Ferragud A, Sabino V, Cottone P. Seeking behavior, place conditioning, and resistance to conditioned suppression of feeding in rats intermittently exposed to palatable food. Behav Neurosci. 2015;129:219–24.
Google Scholar
Johnson WG, Schlundt DG, Barclay DR, Carr-Nangle RE, Engler LB. A naturalistic functional analysis of binge eating. Behav Ther. 1995;26:101–18.
Google Scholar
Smyth JM, Wonderlich SA, Sliwinski MJ, Crosby RD, Engel SG, Mitchell JE, et al. Ecological momentary assessment of affect, stress, and binge-purge behaviors: day of week and time of day effects in the natural environment. Int J Eat Disord. 2009;42:429–36.
Google Scholar
Stein RI, Kenardy J, Wiseman CV, Dounchis JZ, Arnow BA, Wilfley DE. What’s driving the binge in binge eating disorder?: A prospective examination of precursors and consequences. Int J Eat Disord. 2007;40:195–203.
Google Scholar
Escobar C, Salgado R, Rodriguez K, Blancas Vázquez AS, Angeles-Castellanos M, Buijs RM. Scheduled meals and scheduled palatable snacks synchronize circadian rhythms: consequences for ingestive behavior. Physiol Behav. 2011;104:555–61.
Google Scholar
Webb IC, Baltazar RM, Lehman MN, Coolen LM. Bidirectional interactions between the circadian and reward systems: is restricted food access a unique zeitgeber? Eur J Neurosci. 2009;30:1739–48.
Google Scholar
Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162:1403–13.
Google Scholar
Baldo BA, Kelley AE. Discrete neurochemical coding of distinguishable motivational processes: insights from nucleus accumbens control of feeding. Psychopharmacology. 2007;191:439–59.
Google Scholar
Liu Z, Wang Y, Cai L, Li Y, Chen B, Dong Y, et al. Prefrontal cortex to accumbens projections in sleep regulation of reward. J Neurosci. 2016;36:7897–910.
Google Scholar
Chen B, Wang Y, Liu X, Liu Z, Dong Y, Huang YH. Sleep regulates incubation of cocaine craving. J Neurosci. 2015;35:13300–10.
Google Scholar
Roane BM, Taylor DJ. Adolescent insomnia as a risk factor for early adult depression and substance abuse. Sleep. 2008;31:1351–6.
Google Scholar
Wong MM, Brower KJ, Nigg JT, Zucker RA. Childhood sleep problems, response inhibition, and alcohol and drug outcomes in adolescence and young adulthood. Alcohol, Clin Exp Res. 2010;34:1033–44.
Google Scholar
Brower KJ, Perron BE. Sleep disturbance as a universal risk factor for relapse in addictions to psychoactive substances. Med Hypotheses. 2010;74:928–33.
Google Scholar
Morgan PT, Pace-Schott EF, Sahul ZH, Coric V, Stickgold R, Malison RT Sleep, sleep-dependent procedural learning and vigilance in chronic cocaine users: evidence for occult insomnia. Drug alcohol Depend. 2006;82:238–49.
Google Scholar
Pace-Schott EF, Stickgold R, Muzur A, Wigren PE, Ward AS, Hart CL. et al. Sleep quality deteriorates over a binge-abstinence cycle in chronic smoked cocaine users. Psychopharmacology. 2005;179:873–83.
Google Scholar
Pace-Schott EF, Stickgold R, Muzur A, Wigren PE, Ward AS, Hart CL, et al. Cognitive performance by humans during a smoked cocaine binge-abstinence cycle. Am J Drug Alcohol Abuse. 2005;31:571–91.
Google Scholar
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:92–585.
de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998;95:95–7.
Google Scholar
Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469–474. https://doi.org/10.1016/S0896-6273(00)00058-1.
Kilduff TS, Peyron C. The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends Neurosci. 2000;23:359–65. https://doi.org/10.1016/s0166-2236(00)01594-0.
Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A. Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron. 2006;49:589–601.
Google Scholar
Thompson JL, Borgland SL. A role for hypocretin/orexin in motivation. Behav Brain Res. 2011;217:446–53.
Google Scholar
James MH, Charnley JL, Levi EM, Jones E, Yeoh JW, Smith DW, et al. Orexin-1 receptor signalling within the ventral tegmental area, but not the paraventricular thalamus, is critical to regulating cue-induced reinstatement of cocaine-seeking. Int J Neuropsychopharmacol. 2011;14:684–90.
Google Scholar
Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X. et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98:365–76.
Google Scholar
Kisanuki Y. The role of orexin receptor type-1 (OX1R) in the regulation of sleep. Sleep. 2000;23:A91
Hondo M, Nagai K, Ohno K, Kisanuki Y, Willie JT, Watanabe T, et al. Histamine-1 receptor is not required as a downstream effector of orexin-2 receptor in maintenance of basal sleep/wake states. Acta Physiol. 2010;198:287–94.
Google Scholar
Barson JR. Orexin/hypocretin and dysregulated eating: promotion of foraging behavior. Brain Res. 2020;1731:145915.
Google Scholar
Mahler SV, Moorman DE, Smith RJ, James MH, Aston-Jones G. Motivational activation: a unifying hypothesis of orexin/hypocretin function. Nat Neurosci. 2014;17:1298–303.
Google Scholar
Campbell EJ, Barker DJ, Nasser HM, Kaganovsky K, Dayas CV, Marchant NJ. Cue-induced food seeking after punishment is associated with increased Fos expression in the lateral hypothalamus and basolateral and medial amygdala. Behav Neurosci. 2017;131:155–67.
Google Scholar
Dayas CV, McGranahan TM, Martin-Fardon R, Weiss F. Stimuli linked to ethanol availability activate hypothalamic CART and orexin neurons in a reinstatement model of relapse. Biol Psychiatry. 2008;63:152–7.
Google Scholar
James MH, Stopper CM, Zimmer BA, Koll NE, Bowrey HE, Aston-Jones G. Increased number and activity of a lateral subpopulation of hypothalamic orexin/hypocretin neurons underlies the expression of an addicted state in rats. Biol Psychiatry. 2019;85:925–35.
Google Scholar
Martin-Fardon R, Cauvi G, Kerr TM, Weiss F. Differential role of hypothalamic orexin/hypocretin neurons in reward seeking motivated by cocaine versus palatable food. Addiction Biol. 2018;23:6–15.
Google Scholar
Choi DL, Davis JF, Fitzgerald ME, Benoit SC. The role of orexin-A in food motivation, reward-based feeding behavior and food-induced neuronal activation in rats. Neuroscience. 2010;167:11–20.
Google Scholar
Castro DC, Terry RA, Berridge KC. Orexin in rostral hotspot of nucleus accumbens enhances sucrose /‘Liking/’ and intake but scopolamine in caudal shell shifts /‘Liking/’ toward /‘Disgust/’ and /‘Fear/’. Neuropsychopharmacology 2016;41:2101–11.
Terrill SJ, Hyde KM, Kay KE, Greene HE, Maske CB, Knierim AE, et al. Ventral tegmental area orexin 1 receptors promote palatable food intake and oppose postingestive negative feedback. Am J Physiol Regulatory, Integr Comp Physiol. 2016;311:R592–599.
Google Scholar
Barson JR, Ho HT, Leibowitz SF. Anterior thalamic paraventricular nucleus is involved in intermittent access ethanol drinking: role of orexin receptor 2. Addict Biol. 2015;20:469–81.
Google Scholar
Espana RA, Melchior JR, Roberts DC, Jones SR. Hypocretin 1/orexin A in the ventral tegmental area enhances dopamine responses to cocaine and promotes cocaine self-administration. Psychopharmacology. 2011;214:415–26.
Google Scholar
Matzeu A, Kerr TM, Weiss F, Martin-Fardon R. Orexin-A/Hypocretin-1 mediates cocaine-seeking behavior in the posterior paraventricular nucleus of the thalamus via Orexin/Hypocretin Receptor-2. J Pharmacol Exp Ther. 2016;359:273–9.
Google Scholar
Wang B, You ZB, Wise RA. Reinstatement of cocaine seeking by hypocretin (orexin) in the ventral tegmental area: independence from the local corticotropin-releasing factor network. Biol Psychiatry. 2009;65:857–62.
Google Scholar
Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, Koob GF, et al. Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci USA. 2005;102:19168–73.
Google Scholar
Piccoli L, Micioni Di Bonaventura MV, Cifani C, Costantini VJ, Massagrande M, Montanari D, et al. Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats. Neuropsychopharmacology. 2012;37:1999–2011.
Google Scholar
Vickers SP, Hackett D, Murray F, Hutson PH, Heal DJ. Effects of lisdexamfetamine in a rat model of binge-eating. J Psychopharmacol. 2015;29:1290–307.
Google Scholar
Alcaraz-Iborra M, Carvajal F, Lerma-Cabrera JM, Valor LM, Cubero I. Binge-like consumption of caloric and non-caloric palatable substances in ad libitum-fed C57BL/6J mice: pharmacological and molecular evidence of orexin involvement. Behav. Brain Res. 2014;272:93–9.
Google Scholar
Rorabaugh JM, Stratford JM, Zahniser NR. A relationship between reduced nucleus accumbens shell and enhanced lateral hypothalamic orexin neuronal activation in long-term fructose bingeing behavior. PLoS ONE. 2014;9:e95019.
Google Scholar
Cason AM, Aston-Jones G. Attenuation of saccharin-seeking in rats by orexin/hypocretin receptor 1 antagonist. Psychopharmacology. 2013;228:499–507.
Google Scholar
Cason AM, Aston-Jones G. Role of orexin/hypocretin in conditioned sucrose-seeking in female rats. Neuropharmacology. 2014;86:97–102.
Google Scholar
Jupp B, Krivdic B, Krstew E, Lawrence AJ. The orexin(1) receptor antagonist SB-334867 dissociates the motivational properties of alcohol and sucrose in rats. Brain Res. 2011;1391:54–59.
Google Scholar
Nair SG, Golden SA, Shaham Y. Differential effects of the hypocretin 1 receptor antagonist SB 334867 on high-fat food self-administration and reinstatement of food seeking in rats. Br J Pharmacol. 2008;154:406–16.
Google Scholar
Brown RM, Khoo SY-S, Lawrence AJ. Central orexin (hypocretin) 2 receptor antagonism reduces ethanol self-administration, but not cue-conditioned ethanol-seeking, in ethanol-preferring rats. Int J Neuropsychopharmacol. 2013;16:2067–79.
Google Scholar
Shoblock JR, Welty N, Aluisio L, Fraser I, Motley ST, Morton K. et al. Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement. Psychopharmacology. 2011;215:191–203.
Google Scholar
Borgland SL, Chang SJ, Bowers MS, Thompson JL, Vittoz N, Floresco SB, et al. Orexin A/hypocretin-1 selectively promotes motivation for positive reinforcers. J Neurosci. 2009;29:11215–25.
Google Scholar
Espana RA, Oleson EB, Locke JL, Brookshire BR, Roberts DC, Jones SR. The hypocretin-orexin system regulates cocaine self-administration via actions on the mesolimbic dopamine system. Eur J Neurosci. 2010;31:336–48.
Google Scholar
Wiskerke J, James MH, Aston-Jones G. The orexin-1 receptor antagonist SB-334867 reduces motivation, but not inhibitory control, in a rat stop signal task. Brain Res. 2020;1731:146222. https://doi.org/10.1016/j.brainres.2019.04.017.
Matzeu A, Martin-Fardon R. Blockade of Orexin receptors in the posterior paraventricular nucleus of the thalamus prevents stress-induced reinstatement of reward-seeking behavior in rats with a history of ethanol dependence. Front Integr Neurosci. 2020;14:599710.
Google Scholar
James MH, Yeoh JW, Graham BA, Dayas CV. Insights for developing pharmacological treatments for psychostimulant relapse targeting hypothalamic peptide systems. J Addict Res Ther. 2012;S4:008.
Martin-Fardon R, Weiss F. Blockade of hypocretin receptor-1 preferentially prevents cocaine seeking: comparison with natural reward seeking. Neuroreport. 2014;25:485–8.
Google Scholar
Freeman LR, Bentzley BS, James MH, Aston-Jones G. Sex differences in demand for highly palatable foods: role of the Orexin system. Int. J. Neuropsychopharmacol. 2020.
White CL, Ishii Y, Mendoza T, Upton N, Stasi LP, Bray GA. et al. Effect of a selective OX1R antagonist on food intake and body weight in two strains of rats that differ in susceptibility to dietary-induced obesity. Peptides. 2005;26:2331–8.
Google Scholar
James MH, Bowrey HE, Stopper CM, Aston-Jones G. Demand elasticity predicts addiction endophenotypes and the therapeutic efficacy of an orexin/hypocretin-1 receptor antagonist in rats. Eur J Neurosci. 2019;50:2602–12.
Google Scholar
Fragale JE, Pantazis CB, James MH, Aston-Jones G. The role of orexin-1 receptor signaling in demand for the opioid fentanyl. Neuropsychopharmacology. 2019;44:1690–7.
Google Scholar
Fragale JE, James MH, Aston-Jones G. Intermittent self-administration of fentanyl induces a multifaceted addiction state associated with persistent changes in the orexin system. Addiction Biol. 2020;26:e12946.
Mohammadkhani A, Fragale JE, Pantazis CB, Bowrey HE, James MH, Aston-Jones G. Orexin-1 receptor signaling in ventral pallidum regulates motivation for the opioid remifentanil. J Neurosci. 2019;39:9831–40. https://doi.org/10.1523/JNEUROSCI.0255-19.2019.
Mohammadkhani A, James MH, Pantazis CB, Aston-Jones G. Persistent effects of the orexin-1 receptor antagonist SB-334867 on motivation for the fast acting opioid remifentanil. Brain Res. 2019;1731:146461.
Google Scholar
LeSage MG, Perry JL, Kotz CM, Shelley D, Corrigall WA. Nicotine self-administration in the rat: effects of hypocretin antagonists and changes in hypocretin mRNA. Psychopharmacology. 2010;209:203–12.
Google Scholar
James MH, Fragale JE, O’Connor SL, Zimmer BA, Aston-Jones G. The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse. Neuropharmacology. 2020;183:108359
Google Scholar
Prince CD, Rau AR, Yorgason JT, España RA. Hypocretin/Orexin regulation of dopamine signaling and cocaine self-administration is mediated predominantly by Hypocretin Receptor 1. ACS Chem Neurosci. 2015;6:138–46.
Google Scholar
Lawrence AJ, Cowen MS, Yang HJ, Chen F, Oldfield B. The orexin system regulates alcohol-seeking in rats. Br J Pharmacol. 2006;148:752–9.
Google Scholar
Hollander JA, Pham D, Fowler CD, Kenny PJ. Hypocretin-1 receptors regulate the reinforcing and reward-enhancing effects of cocaine: pharmacological and behavioral genetics evidence. Front Behav Neurosci. 2012;6:47.
Google Scholar
Smith RJ, Tahsili-Fahadan P, Aston-Jones G. Orexin/hypocretin is necessary for context-driven cocaine-seeking. Neuropharmacology. 2010;58:179–84.
Google Scholar
Smith RJ, Aston-Jones G. Orexin/hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking. Eur J Neurosci. 2012;35:798–804.
Google Scholar
Matzeu A, Martin-Fardon R. Targeting the Orexin system for prescription opioid use disorder. Brain Sci. 2020;10:4.
Google Scholar
Martin-Fardon, R, Weiss, F. N-2-methyl-6-benzoxazolyl)-N’-1,5-naphthyridin-4-yl urea (SB334867), a hypocretin receptor-1 antagonist, preferentially prevents ethanol seeking: comparison with natural reward seeking. Addict Biol. 2014;19:233–6.
Hopf FW. Recent perspectives on orexin/hypocretin promotion of addiction-related behaviors. Neuropharmacology. 2020;168:108013
Google Scholar
Kwok C, Lei K, Pedrozo V, Anderson L, Ghotra S, Walsh M, et al. Differential importance of nucleus accumbens Ox1Rs and AMPARs for female and male mouse binge alcohol drinking. Sci Rep. 2021;11:231.
Google Scholar
Gentile TA, Simmons SJ, Watson MN, et al. Effects of Suvorexant, a dual orexin/hypocretin receptor antagonist, on impulsive behavior associated with cocaine. Neuropsychopharmacology. 2018;43:1001–9. https://doi.org/10.1038/npp.2017.158.
Muschamp JW, Hollander JA, Thompson JL, Voren G, Hassinger LC, Onvani S, et al. Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area. Proc Natl Acad Sci USA. 2014;111:E1648–1655.
Google Scholar
Calva CB, Fadel JR. Intranasal administration of orexin peptides: mechanisms and therapeutic potential for age-related cognitive dysfunction. Brain Res. 2020;1731:145921. https://doi.org/10.1016/j.brainres.2018.08.024.
Adam JA, Menheere PP, van Dielen FM, Soeters PB, Buurman WA, Greve JW. Decreased plasma orexin-A levels in obese individuals. Int J Obes Relat Metab Disord. 2002;26:274–6.
Google Scholar
Gupta A, Miegueu P, Lapointe M, Poirier P, Martin J, Bastien M, et al. Acute post-bariatric surgery increase in orexin levels associates with preferential lipid profile improvement. PLoS ONE. 2014;9:e84803.
Google Scholar
Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med. 2007;8:373–99.
Google Scholar
Funato H, Tsai AL, Willie JT, Kisanuki Y, Williams SC, Sakurai T, et al. Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. Cell Metab. 2009;9:64–76.
Google Scholar
Kotz C, Nixon J, Butterick T, Perez-Leighton C, Teske J, Billington C. Brain orexin promotes obesity resistance. Ann N Y Acad Sci. 2012;1264:72–86.
Google Scholar
Teske JA, Levine AS, Kuskowski M, Levine JA, Kotz CM. Elevated hypothalamic orexin signaling, sensitivity to orexin A, and spontaneous physical activity in obesity-resistant rats. Am J Physiol Regul Integr Comp Physiol. 2006;291:R889–899.
Google Scholar
Kotz C, Nixon J, Butterick T, Perez-Leighton C, Teske J, Billington C. Brain orexin promotes obesity resistance. Ann N Y Acad Sci. 2012;1264:72–86.
Google Scholar
Lemus MB, Bayliss JA, Lockie SH, Santos VV, Reichenbach A, Stark R. et al. A stereological analysis of NPY, POMC, Orexin, GFAP astrocyte, and Iba1 microglia cell number and volume in diet-induced obese male mice. Endocrinology. 2015;156:1701–13.
Google Scholar
Wortley KE, Chang GQ, Davydova Z, Leibowitz SF. Peptides that regulate food intake: orexin gene expression is increased during states of hypertriglyceridemia. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1454–65.
Google Scholar
Morganstern I, Chang GQ, Karatayev O, Leibowitz SF. Increased orexin and melanin-concentrating hormone expression in the perifornical lateral hypothalamus of rats prone to overconsuming a fat-rich diet. Pharmacol, Biochem Behav. 2010;96:413–22.
Google Scholar
Xi MC, Morales FR, Chase MH. Effects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the cat. Brain Res. 2001;901:259–64.
Google Scholar
Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C. et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell . 1999;98:437–51.
Google Scholar
Fujiki N, Yoshida Y, Ripley B, Mignot E, Nishino S. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep. 2003;26:953–9.
Google Scholar
Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM. et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron. 2001;30:345–54.
Google Scholar
Yoshida Y, Fujiki N, Nakajima T, Ripley B, Matsumura H, Yoneda H, et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci. 2001;14:1075–81.
Google Scholar
Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, Yanagisawa M, et al. Fos expression in orexin neurons varies with behavioral state. J Neurosci. 2001;21:1656–62.
Google Scholar
Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, de Lecea L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature. 2007;450:420–4.
Google Scholar
Carter ME, Adamantidis A, Ohtsu H, Deisseroth K, de Lecea L. Sleep homeostasis modulates hypocretin-mediated sleep-to-wake transitions. J Neurosci. 2009;29:29–49.
Google Scholar
Sasaki K, Suzuki M, Mieda M, Tsujino N, Roth B, Sakurai T. Pharmacogenetic modulation of orexin neurons alters sleep/wakefulness states in mice. PLoS ONE. 2011;6:e20360.
Google Scholar
Tsunematsu T, Kilduff TS, Boyden ES, Takahashi S, Tominaga M, Yamanaka A. Acute optogenetic silencing of orexin/hypocretin neurons induces slow-wave sleep in mice. J Neurosci. 2011;31:10529–39.
Google Scholar
Gerhardstein R, Day R, Rosenthal L. Narcolepsy and other causes of excessive daytime sleepiness. Respir Care Clin N Am. 1999;5:427–46, viii-ix.
Slowik JM, Collen JF, Yow AG. Narcolepsy. StatPearls. 2020.
Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355:39–40.
Google Scholar
Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M. et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27:27–74.
Google Scholar
Rhyne DN, Anderson SL. Suvorexant in insomnia: efficacy, safety and place in therapy. Ther Adv Drug Saf. 2015;6:189–95.
Google Scholar
Norman JL, Anderson SL. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia—critical appraisal of suvorexant. Nat Sci Sleep. 2016;8:239–47.
Google Scholar
Janto K, Prichard JR, Pusalavidyasagar S. An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics. J Clin Sleep Med. 2018;14:1399–408.
Google Scholar
Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opin Drug Metab Toxicol. 2020;16:1063–78.
Google Scholar
Recourt K, de Boer P, Zuiker R, Luthringer R, Kent J, van der Ark P, et al. The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Transl Psychiatry. 2019;9:216.
Google Scholar
Dugovic C, Shelton JE, Aluisio LE, Fraser IC, Jiang X, Sutton SW, et al. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp therapeutics. 2009;330:142–51.
Google Scholar
Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ, et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem. 2010;53:5320–32.
Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, et al. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet. 2011;25:52–61.
Google Scholar
Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K. et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79:2265–74.
Google Scholar
Ardeljan AD, Hurezeanu R. Lemborexant. StatPearls; 2020.
Bonaventure P, Shelton J, Yun S, Nepomuceno D, Sutton S, Aluisio L, et al. Characterization of JNJ-42847922, a selective Orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia. J Pharmacol Exp Ther. 2015;354:471–82.
Google Scholar
Guirguis WR. Sleepwalking as a symptom of bulimia. Br Med J (Clin Res Ed). 1986;293:587–8.
Google Scholar
Iwasa T, Matsuzaki T, Mayila Y, Yano K, Irahara M. Developmental changes in hypothalamic SF-1, POMC, and ERα mRNA expression and their sensitivity to fasting in male and female rats. Endocr J. 2017;64:1157–63.
Google Scholar
Tanno S, Terao A, Okamatsu-Ogura Y, Kimura K. Hypothalamic prepro-orexin mRNA level is inversely correlated to the non-rapid eye movement sleep level in high-fat diet-induced obese mice. Obes Res Clin Pract. 2013;7:e251–7.
Google Scholar
True C, Arik A, Lindsley S, Kirigiti M, Sullivan E, Kievit P. Early high-fat diet exposure causes dysregulation of the Orexin and Dopamine neuronal populations in nonhuman primates. Front Endocrinol (Lausanne). 2018;9:508.
Google Scholar
Beck B, Kozak R, Moar KM, Mercer JG. Hypothalamic orexigenic peptides are overexpressed in young Long-Evans rats after early life exposure to fat-rich diets. Biochem Biophys Res Commun. 2006;342:452–8.
Google Scholar
Chen P-Y, Chen C-H, Chang C-K, Kao CF, Lu ML, Lin SK, et al. Orexin-A levels in relation to the risk of metabolic syndrome in patients with schizophrenia taking antipsychotics. Int J Neuropsychopharmacol. 2018;22:28–36.
Google Scholar
Thannickal TC, John J, Shan L, Swaab DF, Wu MF, Ramanathan L, et al. Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy. Sci Transl Med. 2018;10:447.
Google Scholar
Collier AD, Halkina V, Min SS, Roberts MY, Campbell SD, Camidge K, et al. Embryonic ethanol exposure affects the early development, migration, and location of hypocretin/orexin neurons in zebrafish. Alcohol Clin Exp Res. 2019;43:1702–13.
Google Scholar
Collier AD, Min SS, Campbell SD, Roberts MY, Camidge K, Leibowitz SF. Maternal ethanol consumption before paternal fertilization: stimulation of hypocretin neurogenesis and ethanol intake in zebrafish offspring. Prog Neuropsychopharmacol Biol Psychiatry. 2020;96:109728.
Google Scholar
Yeoh JW, James MH, Adams CD, Bains JS, Sakurai T, Aston-Jones G. et al. Activation of lateral hypothalamic group III metabotropic glutamate receptors suppresses cocaine-seeking following abstinence and normalizes drug-associated increases in excitatory drive to orexin/hypocretin cells. Neuropharmacology. 2019;154:22–33.
Google Scholar
Yeoh JW, James MH, Graham BA, Dayas CV. Electrophysiological characteristics of paraventricular thalamic (PVT) neurons in response to cocaine and cocaine- and amphetamine-regulated transcript (CART). Front Behav Neurosci. 2014;8:280.
Google Scholar
Horvath TL, Gao XB. Input organization and plasticity of hypocretin neurons: possible clues to obesity’s association with insomnia. Cell Metab. 2005;1:279–86.
Google Scholar
Laperchia C, Imperatore R, Azeez IA, Del Gallo F, Bertini G, Grassi-Zucconi G, et al. The excitatory/inhibitory input to orexin/hypocretin neuron soma undergoes day/night reorganization. Brain Struct Funct. 2017;222:3847–59.
Google Scholar
Bunney PE, Zink AN, Holm AA, Billington CJ, Kotz CM. Orexin activation counteracts decreases in nonexercise activity thermogenesis (NEAT) caused by high-fat diet. Physiol Behav. 2017;176:139–48.
Google Scholar
Moorman DE, Aston-Jones G. Orexin/hypocretin modulates response of ventral tegmental dopamine neurons to prefrontal activation: diurnal influences. J Neurosci. 2010;30:15585–99.
Google Scholar
Horvath TL, Diano S, van den Pol AN. Synaptic interaction between hypocretin (orexin) and neuropeptide Y cells in the rodent and primate hypothalamus: a novel circuit implicated in metabolic and endocrine regulations. J Neurosci. 1999;19:19–1087.
Google Scholar
Pollak Dorocic I, Fürth D, Xuan Y, Johansson Y, Pozzi L, Silberberg G. et al. A whole-brain atlas of inputs to serotonergic neurons of the dorsal and median raphe nuclei. Neuron. 2014;83:663–78.
Google Scholar
Muraki Y, Yamanaka A, Tsujino N, Kilduff TS, Goto K, Sakurai T. Serotonergic regulation of the orexin/hypocretin neurons through the 5-HT1A receptor. J Neurosci. 2004;24:7159–66.
Google Scholar
Saito YC, Tsujino N, Abe M, Yamazaki M, Sakimura K, Sakurai T. Serotonergic input to Orexin neurons plays a role in maintaining wakefulness and REM sleep architecture. Front Neurosci. 2018;12:892.
Google Scholar
Allsopp MR, Zaiwalla Z. Narcolepsy. Arch Dis Child. 1992;67:302–6.
Fortuyn HA, Swinkels S, Buitelaar J, Renier WO, Furer JW, Rijnders CA. et al. High prevalence of eating disorders in narcolepsy with cataplexy: a case-control study. Sleep. 2008;31:335–41.
Google Scholar
van Holst RJ, van der Cruijsen L, van Mierlo P, Lammers GJ, Cools R, Overeem S. et al. Aberrant food choices after satiation in human Orexin-deficient narcolepsy type 1. Sleep. 2016;39:1951–9.
Google Scholar
Dimitrova A, Fronczek R, Van der Ploeg J, Scammell T, Gautam S, Pascual-Leone A, et al. Reward-seeking behavior in human narcolepsy. J Clin Sleep Med. 2011;7:293–300.
Google Scholar
Dauvilliers Y, Montplaisir J, Molinari N, Carlander B, Ondze B, Besset A. et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology. 2001;57:2029–33.
Google Scholar
González JA, Jensen LT, Iordanidou P, Strom M, Fugger L, Burdakov D. Inhibitory interplay between Orexin neurons and eating. Curr Biol. 2016;26:2486–91.
Google Scholar
Dahmen N, Becht J, Engel A, Thommes M, Tonn P. Prevalence of eating disorders and eating attacks in narcolepsy. Neuropsychiatr Dis Treat. 2008;4:257–61.
Google Scholar
Sharma S, Kavuru M. Sleep and metabolism: an overview. Int J Endocrinol. 2010;2010:270832
Google Scholar
O’Connor SL, Fragale JE, James MH, Aston-Jones G. The dual orexin/hypocretin receptor antagonist suvorexant reduces addiction-like behaviors for the opioid fentanyl [Preprint]. 2020. Available from: https://www.biorxiv.org/content/10.1101/2020.04.25.061887v1.
Gamble MC, Katsuki F, McCoy JG, Strecker RE, McKenna JT. The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model. Sleep. 2019;43:3
James MH, Fragale JE, Aurora RN, Cooperman NA, Langleben DD, Aston-Jones G. Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer? Neuropsychopharmacology. 2020;45:717–19.
Kotorii N. Treatment strategies when multiple sleep disturbances coexist. The abstract of Japanese society of sleep research meeting 192; Japan, 2015.
Ono H, Kanbayashi T, Iwaki S, et al. Clinical experience with a dual orexin receptor antagonist, Suvorexant (Belsomra) in Japan. J Sleep Disord Med Care. 2018;1:1–5.
Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2:297–307. https://doi.org/10.1016/s1389-9457(00)00065-4.
